Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 14, 2025
Daily News
January 14, 2025
- JGA to Launch Scheme for Requesting Production Ramp-Up in March: President
January 14, 2025
- SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025
January 14, 2025
- Meiji to Invest Up to US$20 Million in MPM BioImpact
January 14, 2025
- MHLW Calls for Proper Use and Ordering of Flu Drugs amid Outbreak
January 14, 2025
- MHLW Starts Inviting Subsidy Applications for Ramp-Up of Key Drugs
January 14, 2025
- MHLW Plans to Submit 6 Bills in 2025 Ordinary Diet Session
January 14, 2025
- MHLW Publishes Panel Report on PMD Act Amendment
January 14, 2025
- Japan Ethical Drug Sales Up 3.3% in November: Crecon
January 14, 2025
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…